The field of tumor immunology has been flooded with exciting therapeutic advances on many fronts. Immunotherapies targeting T cell inhibitory molecules have proven highly effective in some cancers, but additional strategies to induce tumor immunity, such as cancer vaccination, could further increase tumor killing. The combination of both will probably be the way forward in future immunotherapy. In 'Bedside to Bench', Robert Vonderheide and Katherine Nathanson discuss the potential of cancer genomics to identify specific tumor mutations in patients that may be used as targets in cancer vaccines to overcome problems linked to self-antigen epitopes used nowadays. Despite the existing biological and technical hurdles, a framework to implement personalized cancer vaccines in the clinic may be worth considering. In 'Bench to Bedside', Glenn Dranoff peruses the clinical efficacy and detrimental effects of two T cell immune-checkpoint inhibitors, alone and in combination, in patients with melanoma. The studies underscore the need to continue investigating specific tumor events directly involving tumor evasion to develop combinatorial strategies that will reduce drug-related pathology while achieving anti-tumor efficacy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines
Scientific Reports Open Access 02 October 2019
-
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
Genome Medicine Open Access 30 April 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Topalian, S.L., Weiner, G.J. & Pardoll, D.M. J. Clin. Oncol. 29, 4828–4836 (2011).
Riley, J.L. N. Engl. J. Med. 369, 187–189 (2013).
Schlom, J. J. Natl. Cancer Inst. 104, 599–613 (2012).
Cheever, M.A. et al. Clin. Cancer Res. 15, 5323–5337 (2009).
Kreiter, S., Castle, J.C., Tureci, O. & Sahin, U. OncoImmunology 1, 768–769 (2012).
Hacohen, N., Fritsch, E.F., Carter, T.A., Lander, E.S. & Wu, C.J. Cancer Immunol. Res. 1, 11–15 (2013).
Carbone, D.P. et al. J. Clin. Oncol. 23, 5099–5107 (2005).
Sampson, J.H. et al. Mol. Cancer Ther. 8, 2773–2779 (2009).
Wedén, S. et al. Int. J. Cancer 128, 1120–1128 (2011).
Segal, N.H. et al. Cancer Res. 68, 889–892 (2008).
Matsushita, H. et al. Nature 482, 400–404 (2012).
Castle, J.C. et al. Cancer Res. 72, 1081–1091 (2012).
Schreiber, R.D., Old, L.J. & Smyth, M.J. Science 331, 1565–1570 (2011).
Vonderheide, R.H. & Bayne, L.J. Curr. Opin. Immunol. 25, 200–205 (2013).
Schultze, J.L. & Vonderheide, R.H. Trends Immunol. 22, 516–523 (2001).
Predina, J. et al. Proc. Natl. Acad. Sci. USA 110, E415–E424 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Vonderheide, R., Nathanson, K. Immunotherapy at Large: The road to personalized cancer vaccines. Nat Med 19, 1098–1100 (2013). https://doi.org/10.1038/nm.3317
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3317
This article is cited by
-
RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines
Scientific Reports (2019)
-
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
Genome Medicine (2019)
-
Drugging the undruggable RAS: Mission Possible?
Nature Reviews Drug Discovery (2014)
-
The regulatory landscape for actively personalized cancer immunotherapies
Nature Biotechnology (2013)